BioCentury | Apr 1, 2013
Company News

Vivalis, GlaxoSmithKline, Texas A&M University System, U.S. Department of Health and Human Services infectious, biomanufacturing news

...$176 million over the first five years. GSK; Lonza Group Ltd. (SIX:LONN, Basel, Switzerland); and Kalon Biotherapeutics LLC...
BioCentury | Feb 7, 2013
Cover Story

2012 gets a new deal

...Emirates government; U.K. government; U.S. government; World Health Organization >785 Emergent BioSolutions Inc. (NYSE:EBS); GlaxoSmithKline; Kalon Biotherapeutics LLC...
BioCentury | Nov 1, 2012
Strategy

Mess with Texas

...therapeutics 10.6 Mirna Therapeutics Inc. Cancer treatment including drug discovery, development and clinical trials 10.3 Kalon Biotherapeutics LLC...
BioCentury | Jun 25, 2012
Company News

Emergent BioSolutions, Kalon Biotherapeutics, Lonza, GlaxoSmithKline, Novartis, Texas A&M University System infectious news

...will support operation and maintenance costs in subsequent years. Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. Kalon Biotherapeutics LLC...
BioCentury | Jun 19, 2012
Company News

BARDA to establish countermeasures centers

...million over the first five years. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); Lonza Group Ltd. (SIX:LONN); and Kalon Biotherapeutics LLC...
BioCentury | Apr 26, 2012
Strategy

Texas translation

...receiving money in the latest grant round: RNA diagnostics company Asuragen Inc. , biomanufacturing company Kalon Biotherapeutics LLC...
...Prevention & Research Institute of Texas , Austin, Texas Cell Medica Ltd. , London, U.K. Kalon Biotherapeutics LLC...
...by next-generation DNA sequencing 6.8 Cell Medica Ltd. Clinical development of T cell therapies 15.6 Kalon Biotherapeutics LLC...
BioCentury | Mar 31, 2012
Company News

CPRIT awards $81.3M for cancer research

...million grant, will move its headquarters to Texas. Other biotech grants included $7.9 million to Kalon Biotherapeutics LLC...
Items per page:
1 - 7 of 7
BioCentury | Apr 1, 2013
Company News

Vivalis, GlaxoSmithKline, Texas A&M University System, U.S. Department of Health and Human Services infectious, biomanufacturing news

...$176 million over the first five years. GSK; Lonza Group Ltd. (SIX:LONN, Basel, Switzerland); and Kalon Biotherapeutics LLC...
BioCentury | Feb 7, 2013
Cover Story

2012 gets a new deal

...Emirates government; U.K. government; U.S. government; World Health Organization >785 Emergent BioSolutions Inc. (NYSE:EBS); GlaxoSmithKline; Kalon Biotherapeutics LLC...
BioCentury | Nov 1, 2012
Strategy

Mess with Texas

...therapeutics 10.6 Mirna Therapeutics Inc. Cancer treatment including drug discovery, development and clinical trials 10.3 Kalon Biotherapeutics LLC...
BioCentury | Jun 25, 2012
Company News

Emergent BioSolutions, Kalon Biotherapeutics, Lonza, GlaxoSmithKline, Novartis, Texas A&M University System infectious news

...will support operation and maintenance costs in subsequent years. Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. Kalon Biotherapeutics LLC...
BioCentury | Jun 19, 2012
Company News

BARDA to establish countermeasures centers

...million over the first five years. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); Lonza Group Ltd. (SIX:LONN); and Kalon Biotherapeutics LLC...
BioCentury | Apr 26, 2012
Strategy

Texas translation

...receiving money in the latest grant round: RNA diagnostics company Asuragen Inc. , biomanufacturing company Kalon Biotherapeutics LLC...
...Prevention & Research Institute of Texas , Austin, Texas Cell Medica Ltd. , London, U.K. Kalon Biotherapeutics LLC...
...by next-generation DNA sequencing 6.8 Cell Medica Ltd. Clinical development of T cell therapies 15.6 Kalon Biotherapeutics LLC...
BioCentury | Mar 31, 2012
Company News

CPRIT awards $81.3M for cancer research

...million grant, will move its headquarters to Texas. Other biotech grants included $7.9 million to Kalon Biotherapeutics LLC...
Items per page:
1 - 7 of 7